![Salarius Pharmaceuticals Inc](/common/images/company/N_SLRX.png)
Salarius Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing potential new cancer medicines for patients in need of new treatment options. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader. Salarius Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing potential new cancer medicines for patients in need of new treatment options. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
Patients were treated in the dose-escalation portion of the Phase 1/2 study evaluating seclidemstat in combination with azacitidine Investigators reported a 43% overall response rate among 14...
HOUSTON, June 12, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.54 | 34.3949044586 | 1.57 | 7.2 | 1.45 | 16641191 | 2.54718115 | CS |
4 | -0.49 | -18.8461538462 | 2.6 | 7.2 | 1.35 | 4583078 | 2.52379522 | CS |
12 | 1.601 | 314.538310413 | 0.509 | 7.2 | 0.3868 | 1561919 | 2.4963793 | CS |
26 | 1.59 | 305.769230769 | 0.52 | 7.2 | 0.3868 | 768027 | 2.35400141 | CS |
52 | 1.07 | 102.884615385 | 1.04 | 7.2 | 0.3868 | 405478 | 2.25526209 | CS |
156 | -19.64 | -90.2988505747 | 21.75 | 30 | 0.3868 | 483198 | 9.76893316 | CS |
260 | -360.39 | -99.4179310345 | 362.5 | 370.385 | 0.3868 | 615938 | 25.6129475 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.